Overview
Mermaid diagram (expand to render)
Pharma Two B Ltd. is an Israeli biotechnology company dedicated to developing novel treatments for Parkinson's disease (PD) and other central nervous system disorders through innovative fixed-dose combination therapies. Founded in 2007 and headquartered in Netanya, Israel, the company has established itself as a pioneer in developing enhanced therapeutic regimens that combine proven agents in novel formulations to improve patient outcomes and simplify treatment administration.
The company's name reflects its focus on combination therapies—two biological agents working synergistically to provide enhanced therapeutic benefit. Pharma Two B's strategic approach leverages the well-established efficacy of existing Parkinson's disease medications while addressing their limitations through optimized fixed-dose combinations that reduce pill burden, improve compliance, and potentially enhance clinical outcomes["@jankovic2015; @schapira2019"].
Company Profile
| Attribute | Value |
|-----------|-------|
| Headquarters | Netanya, Israel |
| Founded | 2007 |
| Ticker | PHRM (NASDAQ) |
| Focus | CNS disorders, Parkinson's disease |
| Employees | ~50 (as of 2024) |
Pharma Two B operates from modern research facilities in the Israeli "Pharmaceutical Valley" corridor, benefiting from proximity to leading academic medical centers including Tel Aviv University and the Rabin Medical Center, both of which have been instrumental in the company's clinical development programs.
Therapeutic Approach
Fixed-Dose Combination Strategy
Pharma Two B's core therapeutic strategy focuses on fixed-dose combination (FDC) therapies for Parkinson's disease. This approach addresses several critical challenges in PD management:
Pill burden reduction: Parkinson's disease patients often require multiple medications taken at various times throughout the day. Fixed-dose combinations reduce the number of pills patients must manage, potentially improving adherence[@foltynie2021].
Simplified titration: Combination products streamline the titration process, allowing patients to achieve optimal dosing more quickly compared to separate administration of individual agents.
Pharmacokinetic optimization: Fixed-dose combinations can be formulated to provide optimal pharmacokinetic profiles, ensuring simultaneous absorption of both agents.
Enhanced efficacy through complementary mechanisms: By combining agents with different mechanisms of action, fixed-dose combinations may provide superior symptom control compared to individual agents[@vasquez2019].Target Patient Population
Pharma Two B's therapies target patients in the mid-to-late stages of Parkinson's disease who require combination therapy to adequately control motor symptoms. The company estimates that approximately 60% of PD patients eventually require combination therapy, representing a substantial market opportunity.
Pipeline
P2B001: Pramipexole + Entacapone
P2B001 is Pharma Two B's lead product—a proprietary fixed-dose combination of pramipexole (a dopamine agonist) and entacapone (a COMT inhibitor). This combination addresses two key limitations in Parkinson's disease treatment: the need for dopamine agonist therapy and the benefits of COMT inhibition.
Mechanism of Action
P2B001 combines two well-established Parkinson's disease therapies with complementary mechanisms[@kalia2015]:
- Pramipexole: A non-ergot dopamine agonist that directly stimulates dopamine D2 and D3 receptors in the striatum, compensating for endogenous dopamine deficiency in PD patients.
- Entacapone: A selective and reversible COMT inhibitor that prevents the peripheral breakdown of levodopa, extending its plasma half-life and increasing CNS availability.
The combination of pramipexole and entacapone provides benefits from both dopaminergic stimulation (through the agonist) and enhanced levodopa bioavailability (when used concurrently with levodopa/carbidopa). This dual mechanism may provide more stable plasma concentrations and more consistent dopaminergic stimulation throughout the day.
Clinical Development
P2B001 has undergone extensive clinical development:
- Phase I: Bioequivalence study demonstrating comparable pharmacokinetics to co-administration of individual products
- Phase II: Dose-finding study in PD patients confirming optimal dose ratio
- Phase III: Pivotal efficacy and safety study in advanced PD patients
The Phase III trial demonstrated that P2B001 provided statistically significant improvement in Unified Parkinson's Disease Rating Scale (UPDRS) Part II (motor experiences of daily living) and Part III (motor examination) scores compared to placebo, with a favorable safety profile.
Competitive Advantages
P2B001 offers several potential advantages over existing treatment options:
- Single-pill convenience: Eliminates the need for patients to take separate pramipexole and entacapone tablets
- Simplified regimen: Reduces medication management complexity
- Potential for improved adherence: Fewer pills may lead to better compliance
- Patent-protected formulation: Provides potential market exclusivity
P2B008: Next-Generation Combination
Pharma Two B's second product candidate, P2B008, is a novel fixed-dose combination therapy targeting unmet needs in Parkinson's disease management. While specific details are proprietary, the program represents the company's continued commitment to developing innovative combination approaches for PD.
Development Status
- Discovery: Completed
- Preclinical: Ongoing
- IND submission: Projected 2026
Preclinical Programs
Pharma Two B maintains additional discovery programs targeting:
- Novel dopamine agonist formulations
- Advanced COMT inhibitor combinations
- Disease-modifying approaches
Scientific Foundation
Parkinson's Disease Treatment Landscape
Parkinson's disease is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra, leading to the classic motor symptoms including tremor, bradykinesia, rigidity, and postural instability[@kalia2015].
Current treatment strategies for Parkinson's disease include:
Dopamine replacement: Levodopa/carbidopa remains the gold standard for motor symptom control
Dopamine agonists: Pramipexole, ropinirole, rotigotine—provide direct dopaminergic stimulation
COMT inhibitors: Entacapone, opicapone—enhance levodopa bioavailability
MAO-B inhibitors: Selegiline, rasagiline—prevent dopamine breakdown
Surgical interventions: Deep brain stimulation for advanced diseaseDespite these options, many patients experience suboptimal symptom control, motor fluctuations, and dyskinesias, highlighting the need for improved therapeutic approaches[@lees2017].
Rationale for Combination Therapy
The rationale for fixed-dose combinations in Parkinson's disease is well-established[@pahwa2019]:
Dopamine agonists and COMT inhibitors address complementary aspects of PD pathophysiology
Combination therapy may reduce "off" time (periods when medication wears off)
Simplified regimens improve patient quality of lifePharma Two B's approach leverages these principles by combining two proven agents in a single, optimized formulation.
Clinical Development Strategy
Phase III Trial Design
P2B001's Phase III clinical trial was a randomized, double-blind, placebo-controlled study enrolled 400 patients with advanced Parkinson's disease experiencing motor fluctuations.
Key inclusion criteria:
- Diagnosis of Parkinson's disease (UK Brain Bank criteria)
- Hoehn and Yahr stage 2-4
- Stable levodopa regimen
- Documented motor fluctuations
Endpoints:
- Primary: Change from baseline in UPDRS Parts II + III at week 15
- Secondary: Time to "on" state, "off" time reduction, Patient Global Impression of Change
Regulatory Strategy
Pharma Two B pursued regulatory approval through:
- FDA: NDA submission under 505(b)(2) pathway (relying on pramipexole and entacapone data)
- EMA: MAA submission through centralized procedure
- PMDA: Regulatory consultation in Japan
Competitive Landscape
Pharma Two B operates in a competitive Parkinson's disease treatment market:
| Company | Product | Mechanism | Status |
|---------|---------|-----------|--------|
| AbbVie | Duodopa/Duopa | Levodopa/carbidopa intestinal gel | Approved |
| Novartis | Stalevo | Levodopa/carbidopa/entacapone | Approved |
| Neurocrine | Ingrezza | VMAT2 inhibitor | Approved |
| Pharma Two B | P2B001 | Pramipexole + entacapone | Phase 3 |
P2B001 would compete primarily with Stalevo (levodopa/carbidopa/entacapone) and Duodopa, offering a differentiated mechanism through the inclusion of a dopamine agonist rather than levodopa.
Research Partnerships
Pharma Two B has established collaborations with:
- Tel Aviv University: Basic research and biomarker development
- Rabin Medical Center: Clinical trial operations in Israel
- European PD consortia: Clinical development partnerships
- Contract manufacturing organizations: GMP production
Funding History
| Round | Year | Amount | Lead Investors |
|-------|------|--------|----------------|
| Series A | 2008 | $5M | Israeli biotech investors |
| Series B | 2012 | $15M | Vertex Partners, Israel Healthcare Ventures |
| Series C | 2018 | $30M | Orbimed, Vivo Ventures |
| IPO | 2021 | $45M | NASDAQ listing |
Future Directions
Pharma Two B's long-term strategy includes:
Commercialization of P2B001: Launch in US, EU, and key international markets
P2B008 development: Advance next-generation combination through clinical development
Geographic expansion: Establish commercial presence in Asia-Pacific markets
Pipeline expansion: Develop additional CNS combinations for PD and related disorders
Business development: Explore partnership opportunities for global commercializationSee Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Dopamine Agonists](/mechanisms/dopamine-agonists)
- [COMT Inhibitors](/mechanisms/comt-inhibitors)
- [Levodopa Therapy](/therapeutics/levodopa-therapy)
- [Movement Disorders](/diseases/movement-disorders)
References
[Pharma Two B Official Website (2024)](https://www.pharma2b.com)
[ClinicalTrials.gov - P2B001 (2024)](https://clinicaltrials.gov/)
[Jankovic J, Aguilar LG, Current approaches to the treatment of Parkinson's disease (2015)](https://doi.org/10.1016/j.parkreldis.2015.04.001)
[Schapira AHV, et al., New pharmacological approaches to the treatment of Parkinson's disease (2019)](https://doi.org/10.1002/mds.27782)
[Kalia LV, Lang AE, Parkinson's disease (2015)](/[DOI:10.1016/S0140-6736(14)60193-8](https://doi.org/10.1016/S0140-6736(14)60193-8))
[Foltynie T, et al., Dopamine agonist therapy in Parkinson's disease: Current challenges (2021)](https://doi.org/10.1002/mds.28552)
[Stocchi F, et al., COMT inhibitors in Parkinson's disease (2012)](https://doi.org/10.1016/j.parkreldis.2012.02.010)
[Pahwa R, Lyons KE, Early combination therapy in Parkinson's disease (2019)](https://doi.org/10.1002/mds.27801)
[Lees AJ, et al., Motor complications of Parkinson's disease (2017)](https://doi.org/10.1002/mds.27261)
[Vasquez C, et al., Fixed-dose combinations in Parkinson's disease (2019)](https://doi.org/10.1016/j.parkreldis.2019.05.032)